Back to the Top 100
Synchron logo

Rank 64MedTech & Devices

Synchron

Develops endovascular brain-computer interfaces implanted via the blood vessels to restore motor function.

Visit website
Signal Score
84.7
Total raised
$145M
Stage
Series C
Founded
2016
Headquarters
Brooklyn, USA
Region
North America

Their signal

Competes with Neuralink using a safer, minimally invasive endovascular delivery method that avoids open-brain surgery, backed by key clinical trials and major tech-pioneer investors.

Signal Score 84.7editorial estimate, see how it is built
Capital (25% weight)86

Total raised, quality of investors and recency of the last round.

Growth (25% weight)79

Revenue trajectory, customer count, hiring and market pull.

Clinical & regulatory (20% weight)83

Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.

Team (15% weight)91

Founder track record, clinical depth on the bench and technical leadership.

Online visibility (15% weight)88

Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.

Also in MedTech & Devices

ShareLink copied

Did we miss something?

Change, add or remove details on this company. Our desk reviews every request.

Figures are subjective research desk estimates compiled from public sources and refreshed monthly, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.